Targeting Diagnosis of High‐Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation: An Experimental Study.

MLA

Xie, Fang, et al. “Targeting Diagnosis of High‐Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation: An Experimental Study.” Journal of Ultrasound in Medicine, vol. 41, no. 11, Nov. 2022, pp. 2789–802. EBSCOhost, https://doi.org/10.1002/jum.15967.

APA

Xie, F., Yan, L., Li, Y., Lan, Y., Xiao, J., Zhang, M., Jin, Z., Zhang, Y., Tian, X., Zhu, Y., Li, Z., & Luo, Y. (2022). Targeting Diagnosis of High‐Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation: An Experimental Study. Journal of Ultrasound in Medicine, 41(11), 2789–2802. https://doi.org/10.1002/jum.15967

Chicago

Xie, Fang, Lin Yan, Yi‐Ming Li, Yu Lan, Jing Xiao, Ming‐Bo Zhang, Zhuang Jin, et al. 2022. “Targeting Diagnosis of High‐Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation: An Experimental Study.” Journal of Ultrasound in Medicine 41 (11): 2789–2802. doi:10.1002/jum.15967.